Cambridge PET Neurochemist Training Programme

剑桥 PET 神经化学家培训计划

• 批准号: G0900903/1
• 负责人: Franklin Aigbirhio
• 金额: $ 76.72万
• 依托单位: University of Cambridge
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2010
• 资助国家: 英国
• 起止时间: 2010 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0900903%2F1
• 关键词: Cambridge; PET; Neurochemist; Training; Programme

Some radioactive molecules emit gamma radiation that can be detected outside the body and so when injected into humans and animals, in safe low levels, can be used to generate images, using sophisticated scanners, of the brain for biomedical research and clinical diagnosis. However, the molecules have to be designed to target the sites of the brain to be investigated, which is done by attaching a biological compound to the radioactive molecule to create products called radiopharmaceuticals. Due to the severe lack of scientists in the UK who have the specialised skills to design and prepare these radiopharmaceuticals we plan to recruit and train a scientist to join our multidisplicinary team. To achieve this we have created a bespoke training programme which will involve learning from researchers in academia and industry, who are either developing and/or using this imaging technology. As part of this training the scientist will help design new radiopharmaceuticals that would then be used in our on-going research programmes to understand the biological mechanisms of some major diseases and disorders of the brain, and thereby identify some possible treatments. For this specific programme we would be undertaking research projects on Alzheimer?s disease, depression, schizophrenia, obsessive compulsive disorder and drug addiction.

一些放射性分子发出的伽马辐射可以在体外被检测到，因此当以安全的低水平注射到人类和动物体内时，可以使用先进的扫描仪生成大脑图像，用于生物医学研究和临床诊断。然而，这些分子必须设计成针对要研究的大脑部位，这是通过将生物化合物附着到放射性分子上以创建称为放射性药物的产品来完成的。由于英国严重缺乏具备设计和制备这些放射性药物专业技能的科学家，我们计划招募和培训一名科学家加入我们的多学科团队。为了实现这一目标，我们创建了一个定制培训计划，其中包括向学术界和工业界的研究人员学习，他们正在开发和/或使用这种成像技术。作为培训的一部分，科学家将帮助设计新的放射性药物，然后将其用于我们正在进行的研究项目，以了解一些主要疾病和大脑紊乱的生物机制，从而确定一些可能的治疗方法。对于这个具体项目，我们将开展有关阿尔茨海默病、抑郁症、精神分裂症、强迫症和毒瘾的研究项目。